Citation Impact
Citing Papers
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
2011 Standout
Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric Cancer
2011 Standout
Antitumour effect of polyoxomolybdates: induction of apoptotic cell death and autophagy in in vitro and in vivo models
2007
Gastric cancer
2016 Standout
Triple-negative breast cancer molecular subtyping and treatment progress
2020 Standout
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
2011 Standout
American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee
2012 Standout
Etoposide: four decades of development of a topoisomerase II inhibitor
1998 Standout
OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines
2008 Standout
Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: superiority of doxorubicin.
1997
Selection of adjuvant chemotherapy for treatment of node-positive breast cancer
2005
Perspectives on cancer therapy-induced mucosal injury
2004 Standout
EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT)
2003 Standout
OARSI guidelines for the non-surgical management of knee osteoarthritis
2014 Standout
Endometriosis
2009 Standout
Articular cartilage repair: basic science and clinical progress. A review of the current status and prospects
2002 Standout
The Otolaryngologic Manifestations of Gastroesophageal Reflux Disease (GERD): A Clinical Investigation of 225 Patients Using Ambulatory 24‐Hour pH Monitoring and an Experimental Investigation of the Role of Acid and Pepsin in the Development of Laryngeal Injury
1991 Standout
Nanoparticle therapeutics: an emerging treatment modality for cancer
2008 Standout
Anthrazykline in der Krebstherapie
1997 Standout
COX-2 Inhibitors and Their Role in Gynecology
2002
IgG4-Related Disease
2012 Standout
Polyoxometalates: Building Blocks for Functional Nanoscale Systems
2010 Standout
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Feasibility study of adjuvant chemotherapy with S-1 plus cisplatin for gastric cancer
2010
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
Current Pharmacological Treatment of Osteoarthritis
1996
Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer
1996
Drug-Induced Diarrhoea
2000
Lack of Efficacy of Acetaminophen in Treating Symptomatic Knee Osteoarthritis
2003
Riedel's Thyroiditis and Multifocal Fibrosclerosis are part of the IgG4‐related systemic disease spectrum
2010
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
2010 Standout
Epirubicin
1993
Validity and Reliability of the Reflux Symptom Index (RSI)
2002 Standout
Need for common internal controls when assessing the relative efficacy of pharmacologic agents using a meta-analytic approach: Case study of cyclooxygenase 2-selective inhibitors for the treatment of osteoarthritis
2005
Management of Patients With Ulcer Bleeding
2012 Standout
Epirubicin
1997
Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.
1998
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
2014 Standout
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
2012 Standout
Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02 and 07 trials
2005
Gastric cancer
2020 Standout
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2019 Standout
IgG4-related disease
2014 Standout
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Epirubicin-Docetaxel Combination in First-Line Chemotherapy for Patients With Metastatic Breast Cancer
2001
A Risk-Benefit Assessment of Anthracycline Antibiotics in Antineoplastic Therapy
1996
A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling
2006
The Value of Adjuvant Treatment in Young Women with Breast Cancer
2002
Gastrointestinal Safety of Cyclooxygenase-2 Inhibitors: A Cochrane Collaboration Systematic Review
2007
Antibiotic-Associated Diarrhea
2002 Standout
Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy
2007
Treatment of painful temporomandibular joints with a cyclooxygenase-2 inhibitor: a randomized placebo-controlled comparison of celecoxib to naproxen
2004
Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway
2017 StandoutNobel
Docetaxel for the adjuvant treatment of early nodepositive breast cancer: a single technology appraisal
2009
Impact on Survival of Time From Definitive Surgery to Initiation of Adjuvant Chemotherapy for Early-Stage Breast Cancer
2006
Prevention of NSAID-induced gastroduodenal ulcers
2002
Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer
2010
Dissemination and publication of research findings: an updated review of related biases
2010 Standout
Guidelines for the Primary Prevention of Stroke
2014 Standout
Epirubicin Increases Long-Term Survival in Adjuvant Chemotherapy of Patients With Poor-Prognosis, Node-Positive, Early Breast Cancer: 10-Year Follow-Up Results of the French Adjuvant Study Group 05 Randomized Trial
2005
Randomized, Controlled Trial of Cyclophosphamide, Methotrexate, and Fluorouracil Versus Cyclophosphamide, Doxorubicin, and Fluorouracil With and Without Tamoxifen for High-Risk, Node-Negative Breast Cancer: Treatment Results of Intergroup Protocol INT-0102
2005
Screening for hyperglycaemia in pregnancy: a rapid update for the National Screening Committee
2010 StandoutNobel
Temporomandibular Disorders
2008 Standout
Anthraquinones As Pharmacological Tools and Drugs
2016 Standout
Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors
2009
Works of E. Woods being referenced
High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomised trial
2005
Design and Rationale of a Randomised Comparison of Cyclophosphamide, Methotrexate and Fluorouracil vs Fluorouracil, Epirubicin and Cyclophosphamide in Node-Positive Premenopausal Women with Operable Breast Cancer
1993
Randomised trial of epirubicin alone versus 5-fluorouracil, epirubicin and mitomycin C in locally advanced and metastatic carcinoma of the pancreas
1991
Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG
2005
Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group.
1996
Treatment of hyper-IgG4 disease with sequential corticosteroids and tamoxifen – case report and review of the literature
2009
Comparative Efficacy and Safety of Celecoxib and Naproxen in the Treatment of Osteoarthritis of the Hip
2001
Double-blind comparison of efficacy and gastroduodenal safety of diclofenac/misoprostol, piroxicam, and naproxen in the treatment of osteoarthritis.
1993
The Angelchik Antireflux Prosthesis Effects on the Lower Esophageal Sphincter of Primates
1983
Epirubicin Plus Tamoxifen Versus Tamoxifen Alone in Node-Positive Postmenopausal Patients With Breast Cancer: A Randomized Trial of the International Collaborative Cancer Group
1999